RecruitingPhase 2NCT05704166

PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients

Studying Acute lung injury

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fujian Medical University Union Hospital
Principal Investigator
Yong Yang, Doctor
Director of the radiotherapy department
Intervention
Pirfenidone/Placebo(drug)
Enrollment
214 target
Eligibility
18-75 years · FEMALE
Timeline
20232026

Study locations (1)

Collaborators

Beijing Continent Pharmaceutical Co, Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05704166 on ClinicalTrials.gov

Other trials for Acute lung injury

Additional recruiting or active studies for the same condition.

See all trials for Acute lung injury

← Back to all trials